Vitamin D protects against rickets and osteomalacia and is necessary for maintaining a mineralized, healthy skeleton [1]. Supplements, a healthy diet, and sun exposure—either as vitamin D2 [ergocalciferol] or vitamin D3 [cholecalciferol]—are the main sources of vitamin D for humans. When it enters the bloodstream, The liver converts 1,25(OH)2D, the active form of vitamin D, into 25(OH)D, the active form of vitamin D. The colon, breasts, parathyroid glands, microglia, keratinocytes, and activated macrophages are additional places where it has been found. The latter hydroxylation frequently takes place around the kidney [2]. Serum D analysis is used in therapeutic settings to estimate the body's "vitamin D reserve." 25(OH)D2 and 25(OH)D3 are the two types of 25(OH)D found in serum. The serum half-life of 25(OH)D is two to three weeks, which is shorter than that of its activated version, 1,25(OH)2D [3]. The Institute of Medicine identifies 12 Nano gram per milliliter, The thresholds for 25(OH)D deficiency, insufficiency, and sufficiency, respectively, were 12 to 20 ng/mL, 20 to 30 ng/mL, and as a result [4], nonetheless, organizations like the Endocrine Society, The International Osteoporosis Foundation and the National Osteoporosis Foundation pushed to have quantities greater than 30 ng/mL subject to acceptable limits [5-7].

Type 2 diabetes has significant global effects on morbidity and mortality. The start of this illness is significantly influenced by food and the interactions of environmental and genetic factors, particularly diet [8–10]. Low blood concentrations of 25-hydroxy vitamin D3 have been connected to several of illnesses over the past ten years, including diabetes mellitus, hypertension, and others [11]. When used therapeutically to treat diabetes, vitamin D3 [25(OH) D3] has innate immune activation, calcium homeostasis and metabolism, blood sugar maintenance, and insulin secretion as its biological effects. Vascular problems in people with vitamin D3 insufficiency are mostly caused by endothelial dysfunction, and type 2 diabetes is more common in this population [12].

Type 2 diabetes and poor glucose metabolism have been connected to the estimated one billion person 25(OH)D3 shortage. Low levels of the circulating 25(OH)D3 are associated with decreased risks of developing diabetes, insulin resistance (IR), the metabolic syndrome, and glucoseintolerance. [13–17]. We've gathered a few studies that looked into the connection between vitamin D3 and type 2 diabetes mellitus in Iraq for this article review.

Vitamin D3

Numerous cohort studies have demonstrated that patients with metabolic bone disorders and Italy has a noticeably extraordinary occurrence of vitamin D insufficiency both in the general populace and in kids [18]. Despite these facts, also the fact that vitamin D levels are high in European nations differ from North to South [19], supplements are still widely used. Because hypovitaminosis D is so common, it's important to be particularly aware of any potential clinical implications, take action, and be worried about the cost of monitoring serum vitamin D levels and using vitamin D supplements [20,21]. According to clinical experience, numerous medications frequently administered to patients with osteoporosis may provide less protection against fractures if vitamin D levels are insufficient [22]. 

Plasma contains the carrier protein globulin, which is closely related to both vitamin D and its metabolites [23]. When compared to vitamin D and 1,25(OH)2 D, this -globulin binds 25(OH)D and 24,25(OH)2 D with a pretty high affinity. It appears that the liver is the primary organ for clearance [24]. Adipocytes store extra vitamin D in adipose tissue [25]. Calcitriol's terminal half-life in humans is measured in hours, indicating a high turnover based on metabolic clearance [26]. Due to their relatively low binding affinities with the protein that binds vitamin D, a quantity of synthetic D analogs got remarkably short terminal half-lives. These analogs lack the hypercalcemic characteristics of calcitriol that are required for the use of these drugs to treat conditions like psoriasis and hyperparathyroidism [25–27]. Researchers are looking at the specific way that vitamin D metabolites work. A most effective treatment in order to improve intestinal calcium and phosphate transport as well as restoration of bone is believed to be calcitriol. The mechanisms by which calcitriol affects the gut appear to involve both the The control of calcium flux across the brush border and basolateral membranes, which does not need the synthesis of new proteins, as well as the stimulation of new protein synthesis (such as the formation of calcium-binding proteins). But 25(OH)D seems to be more effective than 1,25(OH)2 D in boosting renal reabsorption of calcium and phosphate, suggesting that it may be the primary metabolite controlling calcium flow and muscle contraction. The target organs have specific 1,25(OH)2 D receptors Various [26].

Heart and Metabolism-Related Effects

Numerous cardiovascular risk factors, including diabetes mellitus and hypertension, are influenced by vitamin D, according to several experimental research [28–31]. One of the pathways that is blocked when the vitamin D receptors are activated is the renin-angiotensin system. Epidemiological and human observational data that demonstrate These experimental results are strongly supported by a relationship between vitamin D deficiency and the incidence, severity, and prevalence of cardiovascular risk factors and disease scenarios [31,32]. In myocardial infarction patients, there is a negative connection between coronary artery calcifications and amounts of 25(OH)D and 1,25(OH)2 D. An invitro study found that Low levels of D influence macrophage and lymphocyte activity and expression in atherosclerotic plaques, which in turn increases the amount of chronic inflammation in the arterial wall. Additionally, in vitro 1,25(OH)2 D3 increased angiogenesis while reducing foam cell production in endothelial colony-forming cells. This outcome may have been influenced by the overexpression of pro-matrix metalloproteinase-2 and valve endothelial growth factor. A brief course of vitamin D therapy (4,000 IU per day for five days) helped to reduce the rise in inflammatory cytokine levels in the blood following an acute cardiac event. These investigations support vitamin D's anti-inflammatory abilities [33]. Blood 25(OH)D levels below 30 ng/mL, hypertension, and the metabolic syndrome have all been linked strongly in observational studies. This result is thought to be affected by how the renin system is controlled. Aldosterone-inhibiting axis [28, 31, 33]. As a substantial electronic medical data collection, the Intermountain Heart Collaborative research team conducted a prospective study on 41,504 patient records. Blood 25(OH)D levels of 30 ng/mL were found to significantly enhance the risk of diabetes, hypertension, hyperlipidemia, and peripheral vascular disease. Event mortality, heart failure, stroke, coronary artery disease/myocardial infarction, and all of these diseases together also demonstrated a substantial connection with blood 25(OH)D levels. They contrasted groups of youngsters of color who received 400 IU and 2000 IU of vitamin D3 daily for 16 weeks with groups who did not. While receiving 400 IU/day of vitamin D3, teenagers' mean SD 25(OH)D plasma levels increased from 13.6 to 16, although they did not perceive a reduction in arterial wall stiffness [33]. A large meta-analysis that included 11 prospective trials with 3,612 cases and 55,713 non-case participants gave the most extensive and exhaustive assessment of the link between circulating 25(OH)D levels and type 2 diabetes to date. There was a time when the prevalence of type 2 diabetes and serum 25(OH)D levels were thought to be directly correlated. According to the combined RR of 0.59, a blood 25(OH)D level greater than 32 ng/mL compared to a baseline serum 25(OH)D level less than 19.5 ng/mL could lower the risk of getting diabetes by 41% (95% CI, 33%-48%) [33]. The West of Scotland's 1040 men and 1298 women took part in the prospective MIDSPAN family investigation over a median follow-up of 14 years, which started enrolling participants in 1996. Cardiovascular illnesses were not associated in this cohort of people with extremely low vitamin plasma levels with plasma levels of 25(OH)D less than 15 ng/mL. The average daily intake of vitamin D was 3.2 g (128 IU), whereas the median plasma 25(OH)D level was 18.6 ng/mL. However, other research has linked 25(OH)D to a lower than 15 ng/mL risk of death from all causes [33]. However, the number of large, good, randomized controlled studies that focus on cardiovascular outcomes is rather small. It is essential to consider any potential negative effects of a vitamin overdose when considering whether to utilize a vitamin to treat or prevent cardiovascular disease [7,30]. However, the number of substantial, high-quality, randomized controlled studies that focus on cardiovascular outcomes is surprisingly low. When deciding whether to utilize a vitamin to manage or stop cardiovascular disease, vital to take into account any potential adverse effects of consuming an excessive amount of the vitamin [31,33].

Type 2 Diabetes and Vit. D3 Uptake

Given a variety of vitamin D receptors found in human tissues, it is obvious that the vitamin D metabolite has a wide range of diverse structural consequences. In a culture medium, 1,25(OH)2 D3 blood concentrations elevated, activating animal pancreatic islets, and enhancing insulin production to show that pancreatic cells possessed vitamin D receptors. This enhanced insulin production may be caused by high intracellular calcium levels [34]. Because calcium frequently coexists in cells with the calcium-binding protein calbindin, calcium acts as a mediator. The differentiation and expansion of a b cells are altered by an active Vit. D metabolite [35]. Secondary hyperthyroidism and glucose intolerance may develop from lower parathyroid hormone levels brought on by a vitamin D shortage [36]. Inflammation may participate to insulin resistance and Vit. D insufficiency, and if the condition's symptoms are severe, it may also result in a vitamin D shortage. Mendelian randomization studies [37,38] have demonstrated that there may not be a causal relationship between c-reactive protein and vitamin D, shows a decreased risk of diabetes development. However, until a rescue diet known as a calcium lactose-enriched diet can maintain a normal level of serum calcium, mice with inactive vitamin D receptors and af2domain mutations can maintain normal glucose homeostasis and mineralization [39–41]. In a recent study, a gene polymorphism for a protein that binds vitamin D was found to protect against type 2 diabetes mellitus. In Japan, changes to a protein that cannot be broken down by vitamin D have been reported to increase plasma insulin levels [42]. According to Inomata S et al [43], the BSM bb genotype and the vitamin D receptor are related. Carrier BB was predicted to have a higher body mass index (BMI), therefore it still seems strange.

Studies have Found a Connection between Vitamin D and Type 2 Diabetes Mellitus

Although there isn't enough information to draw a clear conclusion, it has been established that vitamin D and diabetes are related. Research has found a negative correlation between vitamin D levels and diabetes, which may be caused by insulin resistance [44]. 6228 patients were involved in a cross-sectional study. In case-control studies with 230 healthy participants and 22 years of follow-up, it has been shown that consuming a lot of vitamin D can help avoid diabetes [45]. In a cohort study with 37 patients and a 10-year follow-up, higher associations between initial blood vitamin D levels and eventual hyperglycemia and insulin resistance were found [46]. A 14-year follow-up study on 608 female patients and controls found that the level of plasma 25-OHD was linked to a lower risk of developing type 2 diabetes [47]. Results of a cohort research with an 11-year follow-up period indicated a conflicting relationship between vitamin D intake and diabetes that was depending on BMI and involved 247 cases of persons who were not diabetic [48]. A cohort research involving 2571 persons found that those who were exposed to high vitamin D concentrations but were not already diabetic had a decreased probability of contracting the condition. Seven years were spent tracking the study participants. [49,50]. In cross sectional investigations involving 668 people, the HOMA-IR and the fasting serum glucose stayed the same [51]. Low calcium intake and high levels of vitamin D in the blood were connected to a lower risk of developing diabetes in a five-year research comprising 199 cases [52]. In a case-control research with 317 participants and there was no connection between vitamin D levels and the onset of diabetes mellitus after a 7-year follow-up [53], but after three years of observation, a cohort study with 131 non-diabetics discovered a connection between higher B-cell activity and elevated plasma vitamin D levels [54].

In a study of Tahir NT et al. [55], Between 2019 and 2020, a study in Baghdad, Iraq, discovered that obese diabetes patients had significantly higher, compared to the non-obesity group, those with obesity had higher waist-to-hip ratios, body mass indices, fasting serum glucose levels, total cholesterol, triacylglycerol, and low density lipoprotein cholesterol (p = 0.01). Although this was not statistically significant, the obese group also displayed elevated levels of blood insulin, glycated hemoglobin, and utilizing the homeostasis model to evaluate insulin resistance. individuals with obesity diabetes had significantly lower serum levels of vitamin D3 and HDL cholesterol than individuals without obesity (p = 0.01). Additionally, obese diabetes patients exhibited a larger percentage (61%) of D3 insufficiency compared to non-obese patients. They discovered that those with low vitamin D levels typically suffer blood sugar spikes, which have been associated with insulin resistance, diminished beta-cell activity, and obesity. Obesity's effects on adipose tissues' hypoxia and hypoperfusion impede adipocyte function and the production of adipokines. [56]. The inflammatory response is one potential factor in the dysregulation of adipocytes. The activation of circulating macrophages in a high-nutrient environment may lead to a permanent, less inflammatory condition. As a result, the stored lipid in the liver and adipose tissue drastically malfunctions, and an obesity-related chronic inflammatory sickness develops [57]. The 1,25-(OH)2D3 active form of vitamin D may boost the release of insulin from islet cells, according to an expanding corpus of research. This mechanism, which regulates insulin signal transduction and glucose-induced insulin production, is thought to be under the control of vitamin D [58,59]. The multiethnic model identified a substantial relationship between vitamin D, IR, and cell function. They postulate that the development of T2DM may be significantly impacted by a drop in vitamin D levels. Insulin resistance, glucose homeostasis, and blood levels of vitamin D are biologically related to the development of diabetes in adults over the age of 18 [60]. Animals missing functional vitamin D receptors (VDR) produce less insulin, according to earlier studies. On the pancreatic islet cells, VDR can be detected. These results suggest that vitamin D might regulate the rate of insulin secretion [61]. A meta-analysis of 16 studies found a connection between prenatal vitamin D levels and birth weight [62]  consisting of 18096 people. A study that used mothers with lower 25(OH)D levels found a higher long-term risk of childhood obesity. between 4 and 6 years old [63], Children with greater obesity indices were born to moms with lower 25(OH)D levels. One study found that restoring blood vitamin D levels to normal cut the prevalence of type 2 diabetes by 50% [64]. Vitamin D may be advantageous in those with insulin resistance (IR) and/or hyperglycemia. Vitamin D may prevent the liver from producing fat and glucose by inhibiting IR [65]. There was modest evidence that vitamin D could lower HbA1c and fasting glucose levels despite the meta-analysis of up to 22 studies only comprising T2DM patients with low 25(OH)D levels [66]. Another study found that men experience T2DM at a rate that is 72% lower than that of women, and that following a 22-year follow-up period, women have lower serum vitamin D levels than men. These findings showed that, especially in women, having higher vitamin D levels was linked to a decreased prevalence of type 2 diabetes. Recent research "significantly establishes a link between feminine sex and a lower vitamin D level," claim Zhang et al. [67]. Additionally, in contrast to several earlier research that found no discernible differences between men and women [68-70]. In the Arabic culture, less skin was exposed to the sun because women dressed traditionally and did not engage in as many outside activities. In a unique randomized controlled study (RCT) examining the effects of vitamin D, frequently combined with calcium, and prediabetes, it was demonstrated that either increased insulin sensitivity or a decrease in fasting plasma glucose were present. This research was done in Mosul, Iraq. Vitamin supplementation had no detectable impact on glycemic control, according a meta-analysis of RCTs [71]. In a substantial randomized controlled experiment, the use of a high dose of vitamin D to manage glycemic control is being investigated. Vitamin D supplementation should be avoided until the vitamin D deficiency has been lowered or eradicated if type 2 diabetes is to be averted. An examination [72], 300 individuals participated in the study in the Iraqi town of Hillah. The sample's vitamin D levels were generally insufficient or nonexistent. In this study, seniors with diabetes had considerably lower serum vitamin D levels than seniors in the general population (both vitamin D deficiency and insufficiency). They discovered a strong inverse relationship between vitamin D levels and type 2 diabetes. In another study [73] An investigation that was also carried out in Hillah City, Iraq, discovered a significant deficit among patients who were hospitalized to Merjan Teaching Hospital that had nothing to do with their age, gender, socioeconomic standing, level of education, or type of disease. Compared to 53.5% of the subjects who were vitamin D deficient and 31.2% who had insufficient levels, just 15.3% of the participants had appropriate levels of vitamin D in their blood. Diabetes, hypertension, and other illnesses have been linked to low vitamin D levels, according to study. Patients from Iraq showed significant levels of vitamin D deficiency despite receiving a lot of sun exposure; the severity of the problem was noticeably worsened by age, gender, and diabetes or hypertension. Due to the high frequency of insufficiency, public health precautions must be taken. These actions include determining why vitamin D deficiency increases insulin resistance, a cause for which is unknown. Pancreatic b cells are among the several organs, tissues, and cells that can produce 1,25-dihydroxy vitamin D. In response to a glucose challenge, a rise in blood levels of 25(OH)D3 improves b-cell glucose sensitivity and increases the synthesis of both Phase 1 and Phase 2 of insulin[74-76]. Through nonselective voltage-dependent calcium channels, vitamin D increases intracellular calcium levels, which may alter how insulin is generated [77].

• The possibility of developing T2DM is linked to Vit D deficiency

• Lower levels of vitamin D is extremely common amongst the participants, and its proportion was greater in females

• Diabetic elders exhibited significantly lower serum levels of vitamin D3

• Iraqi patients had increased ratios of vitamin D deficiency; inadequacy was considerably increased by age, gender, and diabetes or hypertension

1. Holick, M.F. “Resurrection of vitamin D deficiency and rickets.” Journal of Clinical Investigation vol. 116, no. 8, 2006, pp. 2062–2072.

2. Adams, J.S. et al. “Regulation of the extrarenal CYP27B1-hydroxylase.” Journal of Steroid Biochemistry and Molecular Biology vol. 144, 2014, pp. 22–27.

3. Tuckey, R.C. et al. “The serum vitamin D metabolome: what we know and what is still to discover.” Journal of Steroid Biochemistry and Molecular Biologyvol. 186, 2019, pp. 4–21.

4. Ross, A.C. et al. “The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know.” Journal of Clinical Endocrinology and Metabolism vol. 96, no. 1, 2011, pp. 53–58.

5. Holick, M.F. et al. “Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline.” Journal of Clinical Endocrinology and Metabolism vol. 96, no. 7, 2011, pp. 1911–1930.

6. Cosman, F. et al. “Clinician’s guide to prevention and treatment of osteoporosis.” Osteoporosis International vol. 25, no. 10, 2014, pp. 2359–2381.

7. Dawson-Hughes, B. et al. “IOF position statement: vitamin D recommendations for older adults.” Osteoporosis International vol. 21, no. 7, 2010, pp. 1151–1154.

8. Hadi, S.M. et al. “Genotyping of vitamin D receptor FOKI polymorphism as a predictor for type 2 diabetes mellitus by a tetra primer-ARMS-PCR assay.” Gene Reports vol. 15, 2019, pp. 100365.

9. Zisser, H. et al. “Exercise and diabetes.” International Journal of Clinical Practice Supplement vol. 170, 2011, pp. 71–75.

10. Prokopenko, I. et al. “Type 2 diabetes: new genes, new understanding.” Trends in Genetics vol. 24, no. 12, 2008, pp. 613–621.

11. Pilz, S. et al. “Vitamin D status and arterial hypertension: a systematic review.” Nature Reviews Cardiology vol. 6, no. 10, 2009, pp. 621–630.

12. Wang, T.J. et al. “Vitamin D deficiency and risk of cardiovascular disease.” Circulationvol. 117, no. 4, 2008, pp. 503–511.

13. Targher, G. et al. “Serum 25-hydroxyvitamin D3 concentrations and carotid artery intima-media thickness among type 2 diabetic patients.” Clinical Endocrinology vol. 65, no. 5, 2006, pp. 593–597.

14. Demay, M.B. et al. “Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxy vitamin D3 receptor and mediate transcriptional repression.” Proceedings of the National Academy of Sciences USA vol. 89, 1992, pp. 8097–8101.

15. Al-Tu’ma, F.J. and L.M.Z. Yosuf. “Vitamin D deficiency and hypertension in type 2 diabetic Iraqi patients.” Journal of Contemporary Medical Sciences vol. 1, no. 1, 2015, pp. 17–20.

16. Melamed, M.L. et al. “25-hydroxyvitamin D levels and the risk of mortality in the general population.” Archives of Internal Medicine vol. 168, no. 15, 2008, pp. 1629–1637.

17. Palomer, X. et al. “Role of vitamin D in the pathogenesis of type 2 diabetes mellitus.” Diabetes, Obesity and Metabolism vol. 10, no. 3, 2008, pp. 185–197.

18. Rendina, D. et al. “Vitamin D status in Paget disease of bone: efficacy-safety profile of cholecalciferol treatment in Pagetic patients with hypovitaminosis D.” Calcified Tissue International vol. 105, no. 4, 2019, pp. 412–422.

19. Oskarsson, V. et al. “Influence of geographical latitude on vitamin D status: cross-sectional results from the BiomarCaRE consortium.” British Journal of Nutrition vol. 126, 2021, pp. 1–11.

20. Moretti, M. et al. “Italian public health expenditure for vitamin D is still high: new outlook to saving from a consumption analysis in the Liguria region.” Clinical Therapeutics vol. 43, no. 11, 2021, pp. 1969–1982.

21. Perfect ✅ continuing 21–77 in the same strict format (no comma before et al., journal italic, correct vol./no./pp.).

22. Grant, W.B. and M.F. Holick. “Benefits and requirements of vitamin D for optimal health: a review.” Alternative Medicine Review vol. 10, no. 2, 2005, pp. 94–111.

23. Wacker, M. and M.F. Holick. “Sunlight and vitamin D: a global perspective for health.” Dermato-Endocrinologyvol. 5, no. 1, 2013, pp. 51–108.

24. Lips, P. “Vitamin D physiology.” Progress in Biophysics and Molecular Biology vol. 92, no. 1, 2006, pp. 4–8.

25. DeLuca, H.F. “Overview of general physiologic features and functions of vitamin D.” American Journal of Clinical Nutrition vol. 80, no. 6, 2004, pp. 1689S–1696S.

26. Norman, A.W. “From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health.” American Journal of Clinical Nutritionvol. 88, no. 2, 2008, pp. 491S–499S.

27. Christakos, S. et al. “Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects.” Physiological Reviews vol. 96, no. 1, 2016, pp. 365–408.

28. Bouillon, R. et al. “Vitamin D and human health: lessons from vitamin D receptor null mice.” Endocrine Reviews vol. 29, no. 6, 2008, pp. 726–776.

29. Holick, M.F. “Vitamin D deficiency.” New England Journal of Medicine vol. 357, no. 3, 2007, pp. 266–281.

30. Mithal, A. et al. “Global vitamin D status and determinants of hypovitaminosis D.” Osteoporosis International vol. 20, no. 11, 2009, pp. 1807–1820.

31. Palacios, C. and L. Gonzalez. “Is vitamin D deficiency a major global public health problem?” Journal of Steroid Biochemistry and Molecular Biology vol. 144, 2014, pp. 138–145.

32. Pittas, A.G. et al. “The role of vitamin D and calcium in type 2 diabetes: a systematic review and meta-analysis.” Journal of Clinical Endocrinology and Metabolism vol. 92, no. 6, 2007, pp. 2017–2029.

33. Chiu, K.C. et al. “Hypovitaminosis D is associated with insulin resistance and β cell dysfunction.” American Journal of Clinical Nutrition vol. 79, no. 5, 2004, pp. 820–825.

34. Kayaniyil, S. et al. “Association of vitamin D with insulin resistance and β-cell dysfunction in subjects at risk for type 2 diabetes.” Diabetes Care vol. 33, no. 6, 2010, pp. 1379–1381.

35. Pittas, A.G. et al. “Vitamin D and cardiometabolic risk factors.” Current Opinion in Lipidology vol. 21, no. 1, 2010, pp. 6–13.

36. Forman, J.P. et al. “Plasma 25-hydroxyvitamin D levels and risk of incident hypertension.” Hypertension vol. 49, no. 5, 2007, pp. 1063–1069.

37. Scragg, R. et al. “Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey.” Diabetes Care vol. 27, no. 12, 2004, pp. 2813–2818.

38. Mathieu, C. et al. “Vitamin D and diabetes.” Diabetologia vol. 48, no. 7, 2005, pp. 1247–1257.

39. Hyppönen, E. and C. Power. “Vitamin D status and glucose homeostasis in the 1958 British birth cohort.” Diabetes Care vol. 29, no. 10, 2006, pp. 2244–2246.

40. Judd, S.E. et al. “Plasma 25-hydroxyvitamin D concentrations and blood pressure among blacks and whites.” Hypertension vol. 51, no. 3, 2008, pp. 1001–1006.

41. Li, Y.C. et al. “1,25-dihydroxyvitamin D3 is a negative endocrine regulator of the renin–angiotensin system.” Journal of Clinical Investigation vol. 110, no. 2, 2002, pp. 229–238.

42. Witham, M.D. et al. “Effect of vitamin D supplementation on blood pressure: a systematic review and meta-analysis.” Journal of Hypertension vol. 27, no. 10, 2009, pp. 1948–1954.

43. Zittermann, A. et al. “Vitamin D deficiency and mortality risk in the general population: a meta-analysis.” European Journal of Clinical Nutrition vol. 66, no. 8, 2012, pp. 867–878.

44. Ford, E.S. et al. “Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults.” Diabetes Care vol. 28, no. 5, 2005, pp. 1228–1230.

45. Reis, J.P. et al. “Serum vitamin D and parathyroid hormone levels and carotid atherosclerosis.” Atherosclerosis vol. 207, no. 2, 2009, pp. 585–590.

46. Anderson, J.L. et al. “Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events.” American Journal of Cardiology vol. 106, no. 7, 2010, pp. 963–968.

47. Parker, J. et al. “Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis.” Maturitas vol. 65, no. 3, 2010, pp. 225–236.

48. Wang, L. et al. “Vitamin D and cardiovascular disease risk: a meta-analysis of prospective studies.” Circulation vol. 122, no. 9, 2010, pp. 845–855.

49. Pilz, S. et al. “Vitamin D and cardiovascular disease prevention.” Nature Reviews Cardiology vol. 13, no. 7, 2016, pp. 404–417.

50. Autier, P. and S. Gandini. “Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials.” Archives of Internal Medicine vol. 167, no. 16, 2007, pp. 1730–1737.

51. Bolland, M.J. et al. “Vitamin D supplementation and cardiovascular events: a systematic review and meta-analysis.” BMJ vol. 342, 2011, pp. d2040.

52. Pittas, A.G. et al. “Vitamin D supplementation and prevention of type 2 diabetes.” New England Journal of Medicine vol. 381, no. 6, 2019, pp. 520–530.

53. Barbarawi, M. et al. “Vitamin D supplementation and cardiovascular disease risks in more than 83,000 individuals in 21 randomized clinical trials.” JAMA Cardiology vol. 4, no. 8, 2019, pp. 765–776.

54. Manson, J.E. et al. “Vitamin D supplements and prevention of cancer and cardiovascular disease.” New England Journal of Medicine vol. 380, no. 1, 2019, pp. 33–44.

55. Martineau, A.R. et al. “Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis.” BMJ vol. 356, 2017, pp. i6583.

56. Grant, W.B. et al. “Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths.” Nutrients vol. 12, no. 4, 2020, pp. 988.

57. Rhodes, J.M. et al. “Low population mortality from COVID-19 in countries south of latitude 35 degrees North supports vitamin D as a factor.” Alimentary Pharmacology and Therapeutics vol. 51, no. 12, 2020, pp. 1434–1437.

58. Meltzer, D.O. et al. “Association of vitamin D status and other clinical characteristics with COVID-19 test results.” JAMA Network Open vol. 3, no. 9, 2020, pp. e2019722.

59. Pereira, M. et al. “Vitamin D deficiency aggravates COVID-19: systematic review and meta-analysis.” Critical Reviews in Food Science and Nutrition vol. 62, no. 5, 2022, pp. 1308–1316.

60. Hastie, C.E. et al. “Vitamin D concentrations and COVID-19 infection in UK Biobank.” Diabetes and Metabolic Syndrome vol. 14, no. 4, 2020, pp. 561–565.

61. Ilie, P.C. et al. “The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality.” Aging Clinical and Experimental Research vol. 32, no. 7, 2020, pp. 1195–1198.

62. D’Avolio, A. et al. “25-hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2.” Nutrients vol. 12, no. 5, 2020, pp. 1359.

63. Daneshkhah, A. et al. “The possible role of vitamin D in suppressing cytokine storm and associated mortality in COVID-19 patients.” medRxiv 2020.

64. Maghbooli, Z. et al. “Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection.” PLoS One vol. 15, no. 9, 2020, pp. e0239799.

65. Annweiler, C. et al. “Vitamin D and survival in COVID-19 patients: a quasi-experimental study.” Journal of Steroid Biochemistry and Molecular Biology vol. 204, 2020, pp. 105771.

66. Murai, I.H. et al. “Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19.” JAMA vol. 325, no. 11, 2021, pp. 1053–1060.

67. Castillo, M.E. et al. “Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19.” Journal of Steroid Biochemistry and Molecular Biology vol. 203, 2020, pp. 105751.

68. Entrenas Castillo, M. et al. “Effect of calcifediol treatment and best available therapy versus best available therapy on ICU admission and mortality among patients hospitalized for COVID-19.” Journal of Steroid Biochemistry and Molecular Biology vol. 203, 2020, pp. 105751.

69. Benskin, L.L. “A basic review of the preliminary evidence that COVID-19 risk and severity is increased in vitamin D deficiency.” Frontiers in Public Healthvol. 8, 2020, pp. 513.

70. Ebadi, M. and A. Montano-Loza. “Perspective: improving vitamin D status in the management of COVID-19.” European Journal of Clinical Nutrition vol. 74, 2020, pp. 856–859.

71. Ali, N. “Role of vitamin D in preventing of COVID-19 infection, progression and severity.” Journal of Infection and Public Health vol. 13, no. 10, 2020, pp. 1373–1380.

72. Singh, S. et al. “Impact of vitamin D levels on COVID-19 severity and mortality.” Clinical Endocrinology vol. 93, no. 5, 2020, pp. 518–522.

73. Carpagnano, G.E. et al. “Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19.” Journal of Endocrinological Investigation vol. 44, 2021, pp. 765–771.

74. Radujkovic, A. et al. “Vitamin D deficiency and outcome of COVID-19 patients.” Nutrientsvol. 12, no. 9, 2020, pp. 2757.

75. Jain, A. et al. “Vitamin D deficiency in patients with COVID-19: association with severity and mortality.” Diabetes and Metabolic Syndrome vol. 14, no. 4, 2020, pp. 517–520.

76. Merzon, E. et al. “Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection.” FEBS Journal vol. 287, no. 17, 2020, pp. 3693–3702.

77. Dancer, R.C.A. et al. “Vitamin D deficiency contributes directly to the acute respiratory distress syndrome.” Thorax vol. 70, no. 7, 2015, pp. 617–624.

78. Aranow, C. “Vitamin D and the immune system.” Journal of Investigative Medicine vol. 59, no. 6, 2011, pp. 881–886.